CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The purpose of this study is to compare the usual treatment for acute myeloid leukemia (AML) with two different combinations of treatment.
This trial is part of a larger platform study called myeloMATCH > Find out more.
The purpose of this study is to find out if the addition of a new oral drug to the usual treatment will lower the chance of your primary central nervous system lymphoma (PCNSL) growing or spreading.
This trial is the first step in joining a large research study called myeloMATCH.
The purpose of this study is to see the effects on you and your lymphoma of a new drug combination compared to other drugs that are currently used in standard treatment.
One of the treatments for multiple myeloma is with three medicines, all continued indefinitely until they stop working, or side effects happen. Two are tablets, and the third is an injection. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.
The purpose of this study is to compare the usual treatment for your Hodgkin lymphoma, which is a standard combination of four drugs, versus the standard combination with one drug of the combination replaced with a new drug that we hope will be more effective and cause you fewer side effects.
The purpose of this trial is to find out if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will live longer and have a better quality of life if they start treatment earlier. Some people do not have major symptoms when they are diagnosed with CLL or SLL. Treatment is often started when they show symptoms such as fever, anemia, or night sweats. Studies have shown that early treatment using older chemotherapy drugs doesn’t improve outcomes compared to later treatment.
